Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

A majority of cancers fail to respond to immunotherapy with antibodies targeting immune checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)/PD-1 ligand (PD-L1). Cancers frequently express transforming growth factor-β (TGFβ), which drives immune dysfunction in...

Full description

Saved in:
Bibliographic Details
Published in:Nat Commun
Main Authors: Ravi, Rajani, Noonan, Kimberly A., Pham, Vui, Bedi, Rishi, Zhavoronkov, Alex, Ozerov, Ivan V., Makarev, Eugene, V. Artemov, Artem, Wysocki, Piotr T., Mehra, Ranee, Nimmagadda, Sridhar, Marchionni, Luigi, Sidransky, David, Borrello, Ivan M., Izumchenko, Evgeny, Bedi, Atul
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2018
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5821872/
https://ncbi.nlm.nih.gov/pubmed/29467463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-017-02696-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items